Retrospective Chart Review Study of Patients With PIK3CA-Related Overgrowth Spectrum Who Have Received Alpelisib (EPIK-P1)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04285723 |
|
Recruitment Status :
Completed
First Posted : February 26, 2020
Results First Posted : February 9, 2023
Last Update Posted : February 9, 2023
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
The study was a site-based retrospective non-interventional medical chart review of pediatric and adult male and female patients with PIK3CA-Related Overgrowth Spectrum (PROS) who initiated alpelisib at least 24 weeks before the cut-off date at a MAP site. The study cut-off date was 09-Mar-2020.
Patient-level data were abstracted from medical charts of all eligible patients at all participating sites. Study completion date refers to the last date data was extracted.
Information from patients treated with alpelisib was used to describe the efficacy and safety of alpelisib in PROS patients.
| Condition or disease | Intervention/treatment |
|---|---|
| PIK3CA-Related Overgrowth Spectrum (PROS) | Other: alpelisib |
| Study Type : | Observational |
| Actual Enrollment : | 57 participants |
| Observational Model: | Case-Only |
| Time Perspective: | Retrospective |
| Official Title: | Retrospective Chart Review Study of Patients With PIK3CA-Related Overgrowth Spectrum (PROS) Who Have Received Alpelisib as Part of a Compassionate Use Program (EPIK-P1) |
| Actual Study Start Date : | June 9, 2020 |
| Actual Primary Completion Date : | April 16, 2021 |
| Actual Study Completion Date : | April 16, 2021 |
| Group/Cohort | Intervention/treatment |
|---|---|
|
alpelisib
Patients treated with alpelisib
|
Other: alpelisib
Retrospective observational case-only study. There is no treatment allocation. Patients with severe or life-threatening PROS who have received alpelisib as part of a compassionate use program were invited to participate. |
- Percentage of Patients Responders and Non-responders at Week 24 [ Time Frame: Index date and week 24 or 6 months (± 4 weeks) ]Response is defined by achieving at least 20% reduction from index date in the sum of measurable target lesion volume (1 to 3 lesions, via central review of imaging scans), provided that none of the individual target lesions have ≥ 20% increase from index date and in absence of progression of non-target lesions and without new lesions.
- Percent Change in the Sum of Measurable Target Lesion Volume [ Time Frame: Index date, week 4, 12 , 24, 52 and end of study (up to a maximum of week 187) ]
Percent change in the sum of measurable target lesion (1 to 3 lesions) volume, as assessed by a central review of imaging scans, as measured by the change between the index date (or up to 24 weeks prior) and key time-points following the index date.
The index date: (baseline) was defined as the date of alpelisib initiation End of study: patients were followed up to a maximum of 187 weeks.
- Percent Change in the Sum of All Measurable Lesion Volume [ Time Frame: Index date, week 4, 12 , 24, 52 and end of study (up to a maximum of week 187) ]
Percent change in the sum of all measurable (target and non-target) lesion volume, as assessed by a central review of imaging scans, as measured by the change between the index date (or up to 24 weeks prior) and key time-points following the index date.
The index date (baseline) was defined as the date of alpelisib initiation. End of study: patients were followed up to a maximum of 187 weeks As no measurable non-target lesions were identified, the results for changes in the sum of all measurable (target and non-target) lesion volume were identical to the results presented for measurable target lesion.
- Percent Change in the Sum of All Measurable Non-target Lesion Volume [ Time Frame: Index date, week 4, 12 , 24, 52 and end of study (up to a maximum of week 187) ]
Percent change in the sum of all measurable non-target lesion volume, as assessed by a central review of imaging scans, as measured by the change between the index date (or up to 24 weeks prior) and key time-points following the index date.
The index date (baseline) was defined as the date of alpelisib initiation.
- Mean Duration of Response (DoR) [ Time Frame: Up to 187 weeks ]
Duration of response is defined as the time from first documented response, to the date of the first documented disease progression or death due to any cause.
Response is defined by achieving at least 20% reduction from index date in the sum of measurable target lesion volume (1 to 3 lesions, via central review of imaging scans), provided that none of the individual target lesions have ≥ 20% increase from index date and in absence of progression of non-target lesions and without new lesions.
Disease progression is defined as an increase of any individual target lesions of ≥ 20% in volume from previous assessment, progression of non-target PIK3CA Related Overgrowth Spectrum (PROS) lesions or appearance of a new PROS lesion.
- Reasons for Discontinuation of Concomitant PROS-related Non-drug Treatments [ Time Frame: Up to 187 weeks ]
Number of participants with concomitant PIK3CA Related Overgrowth Spectrum (PROS)-related non-drug treatments and other medical interventions by reason for discontinuation.
A patient may have multiple information, but was counted only once in type of other supportive non-drug treatment if more than one type in this category has been reported.
- Participants With Concomitant PROS-related Medications Over Time [ Time Frame: Index date, week 24 and end of study ]
Number of participants with at least one concomitant utilization of PIK3CA Related Overgrowth Spectrum (PROS)-related medication.
End of study: patients were followed up to a maximum of 187 weeks. Results are provided for the full study population as planned and documented in the protocol and SAP, and not by age group.
- Number of PROS-related Completed Surgeries During the Study Period [ Time Frame: Up to 187 weeks ]Number of surgeries by reason of surgery. A patient may have multiple anatomical sites of surgery and types of surgery on the same day.
- Number of Patients With Improvement in Most Frequent PROS-related Signs and Symptoms [ Time Frame: Index date and week 24 or 6 months (± 4 weeks) ]
Improvement in PIK3CA Related Overgrowth Spectrum (PROS) signs and symptoms was defined based on Common Toxicity Criteria (CTC) grade reduction or resolution of the event from index date.
CTC is a set of criteria for the standardized classification of adverse effects of drugs used in cancer therapy. The Common Terminology Criteria for Adverse Events (CTCAE) system is a product of the US National Cancer Institute (NCI). For this study, version 4.03 was used
- Change in Performance Status Score [ Time Frame: Index date and week 24 or 6 months (± 4 weeks) ]
Participants with a change in performance status score (ECOG, Karnofsky, Lansky) between the index date and week 24. Patients completed one questionnaire (ECOG, Karnofsky or Lansky) based on physicians choice.
The Eastern Cooperative Oncology Group (ECOG) score runs from 0 to 5, with 0 denoting perfect health and 5 death. The Karnofsky Performance Score (KPS) and Lansky score run from 0 to 100, where 0 is death and 100 is perfect health.
For the ECOG scale, "improvement" is defined as a decrease by at least 1 point and and "worsening" is defined as an increase by at least 1 point. For the Karnofsky and Lansky scale, "improvement" is defined as an increase by at least 20 points and worsening is defined as a decrease by at least 20 points.
If neither of the criteria for improvement or worsening is met, then it is considered stable.
- Functional Status - Mobility Assessment [ Time Frame: Up to 187 weeks ]
Change in functional status: Mobility severity assessment measured up to the judgment of the investigator.
A patient may have multiple information
- Change From Index Date in Functional Status - School Status During the Study Period [ Time Frame: Index date, week 24 and end of study (up to 187 weeks) ]
Change in functional status: School status during the study period (no attendance, part-time or full time).
Improvement is defined as a shift from reporting of "No attendance" to "Part-time" as well as , "Part-time" or "No attendance" to "Full-time"; Worsening is defined as a shift from reporting of "Part-time" to "No attendance", as well as from "Full-time" to "Part-time" or "No attendance".
If neither of the criteria for improvement or worsening is met, then it is considered stable.
- Change From Index Date in Functional Status - Work Status [ Time Frame: Index date, week 24 and end of study ]
Change in functional status: Work status assessment during the study period (no attendance, part-time, full-time or unemployed).
Improvement is defined as a shift from reporting of "No attendance" to "Part-time" or "Full time", from "Part-time" to "Full-time", as well as from "Unemployed" to "Part-time" or "Full-time" work.
Worsening is defined as a shift from reporting of "Part-time" to "No attendance", "Full-time" to "Part-time" or "No attendance" as well as "Part-time" or "Full-time" to "Unemployed" status.
Change in score is only applicable if both index date and post-index date information are available.
If a patient has more than 1 score reported within the same time window, the worst is considered.
If neither of the criteria for improvement or worsening is met, then it is considered stable.
- Health Resource Utilization (HRU) - Number of Hospitalizations Per Patient [ Time Frame: Up to 187 weeks ]Hospitalizations starting on or after the start of study treatment (index date) or starting prior to and continuing after the start of study treatment are summarized.
- Number of Patients With Grade 3/4 on Laboratory Assessments: Hematology [ Time Frame: Up to 187 weeks ]
Worst post-index date hematology abnormalities based on Common Toxicity Criteria (CTC) grades during the study period.
Grade refers to the severity of the AE: Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living. Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living. Grade 4 Life-threatening consequences; urgent intervention indicated.
Patients are counted only for the worst grade observed post-index date values. Laboratory assessments performed more than 30 days after last study treatment administration date are not summarized.
- Number of Patients With Grade 3/4 on Clinical Assessments - Clinical Chemistry [ Time Frame: 187 weeks ]
Worst post-index date biochemistry abnormalities based on Common Toxicity Criteria (CTC) grades.
Grade refers to the severity of the AE: Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living. Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living. Grade 4 Life-threatening consequences; urgent intervention indicated.
Patients are counted only for the worst grade observed post-index date values. Laboratory assessments performed more than 30 days after last study treatment administration date are not summarized.
- Notable Vital Sign Values During the Study Period - Pediatric Patients [ Time Frame: End of study (up to week 187) ]
Low/High: Indicating abnormal value/change from index date.
High systolic blood pressure: ≥95th percentile of the age and height group Low Systolic blood pressure: ≤5th percentile of the age and height group. High diastolic blood pressure: ≥95th percentile of the age and height group Low diastolic blood pressure: ≤5th percentile of the age and height group. High pulse rate (bpm): 2-3 years: >128; 3-4 years: >123; 4-6 years: >117; 6-8 years: >111; 8-12years: >103; 12-15 years: >96; ≥15 years: >92 Low pulse rate (bpm): 2-3 years: <92; 3-4 years: <86; 4-6 years: <81; 6-8 years: <74; 8-12 years: <67; 12-15 years: <62; ≥15 years: <58.
High weight: increase from baseline of ≥2 Body mass index (BMI) for age percentile categories Low weight: decrease from baseline of ≥2 BMI-for-age percentile categories
- Notable Vital Sign Values During the Study Period - Adult Patients [ Time Frame: End of study (up to week 187) ]
Low/High: Indicating abnormal value/change from index date.
High systolic blood pressure: ≥180 mmHg and increase ≥20 mmHg Low systolic blood pressure: ≤90 mmHg and decrease ≥20 mmHg. High diastolic blood pressure: ≥105 mmHg and increase ≥15 mmHg Low diastolic blood pressure: ≤50 mmHg and decrease ≥15 mmHg. High pulse rate: ≥120 bpm and increase ≥15 bpm Low pulse rate: ≤ 50 bpm and decrease ≥15 bpm. High weight: Increase ≥10% Low weight: Decrease ≥10%
- Number of Participants With Notable ECG Values. [ Time Frame: Up to week 187 ]Notable Electrocardiogram (ECG) values during the study period
- Growth and Development in Pediatric Population [ Time Frame: Week 24 or 6 months (± 4 weeks) ]
Assessed in patients who were aged <18 years at the time of alpelisib initiation.
SDS (standard deviation scores) for height and BMI are obtained from the WHO Growth Charts, and SDS for height and weight velocity are obtained from Baumgartner et al. (1986). Height or weight velocity is a variable derived from the measurement of height or weight at different times and represents the increase in height or weight during a fixed period.
SD- scores are used to describe how far a measurement is from the median (average).
Weight-for-age reference data are not available beyond age 10.
- Overview of Number of Patients With Adverse Events (AEs) [ Time Frame: Up to 187 weeks ]
A patient with multiple severity grades for an AE is only counted under the maximum grade.
All grades includes any AEs with missing grade. Grade refers to the severity of the AE: Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living. Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living. Grade 4 Life-threatening consequences; urgent intervention indicated.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 2 Years and older (Child, Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
Inclusion Criteria:
- Patient (adult or pediatric) is ≥ 2 years of age
- Patient has a physician confirmed/documented diagnosis of PROS
- Patient has a documented evidence of a mutation in the PIK3CA gene
- Patient's condition was assessed by the treating physician as severe or life threatening and treatment was deemed necessary
- Patient has been treated with at least one dose of alpelisib, initiated on or before 23-Sep-2019 (i.e. at least 24 weeks before the cut-off date of the 09-Mar-2020)
- Patient has medical chart history available during enrollment in the Novartis MAP
- Patient (or parent/guardian in case of pediatric patient) consented to participate in the study (as required by local ethics regulations) Inclusion criteria for MAP enrollment (assessed at the time of alpelisib initiation)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04285723
| United States, Massachusetts | |
| Boston Childrens Hospital | |
| Boston, Massachusetts, United States, 02215 | |
| Australia, Victoria | |
| Novartis Investigative Site | |
| Parkville, Victoria, Australia, 3052 | |
| France | |
| Novartis Investigative Site | |
| Montpellier cedex 5, Herault, France, 34059 | |
| Novartis Investigative Site | |
| Dijon, France, 21000 | |
| Novartis Investigative Site | |
| Paris cedex 15, France, 75015 | |
| Ireland | |
| Novartis Investigative Site | |
| Dublin, Ireland, 12 | |
| Spain | |
| Novartis Investigative Site | |
| Madrid, Spain, 28046 | |
| Study Director: | Novartis Pharmaceuticals | Novartis Pharmaceuticals |
Documents provided by Novartis ( Novartis Pharmaceuticals ):
| Responsible Party: | Novartis Pharmaceuticals |
| ClinicalTrials.gov Identifier: | NCT04285723 |
| Other Study ID Numbers: |
CBYL719F12002 |
| First Posted: | February 26, 2020 Key Record Dates |
| Results First Posted: | February 9, 2023 |
| Last Update Posted: | February 9, 2023 |
| Last Verified: | May 2022 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
alpelisib PIK3CA BYL719 |
PROS Retrospective chart review study EPIK-P1 |